The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Even among blue-chip stocks, not all investments are created equal - which is why we built StockStory to help you navigate the market. That said, here is one S&P 500 stock that is leading the market forward and two that may struggle.
Two Stocks to Sell:
Expeditors (EXPD)
Market Cap: $23.04 billion
Expeditors (NYSE: EXPD) offers air and ocean freight as well as brokerage services.
Why Do We Think Twice About EXPD?
- Flat sales over the last five years suggest it must find different ways to grow during this cycle
- Gross margin of 13.5% reflects its high production costs
- Diminishing returns on capital suggest its earlier profit pools are drying up
At $178.24 per share, Expeditors trades at 23.3x forward P/E. Dive into our free research report to see why there are better opportunities than EXPD.
Northern Trust (NTRS)
Market Cap: $34.36 billion
Founded in 1889 during Chicago's post-Great Fire rebuilding boom, Northern Trust (NASDAQ: NTRS) provides wealth management, asset servicing, and banking solutions to corporations, institutions, families, and high-net-worth individuals globally.
Why Does NTRS Worry Us?
- Annual revenue growth of 6.9% over the last five years was below our standards for the financials sector
Northern Trust’s stock price of $187.67 implies a valuation ratio of 15.8x forward P/E. Check out our free in-depth research report to learn more about why NTRS doesn’t pass our bar.
One Stock to Buy:
DexCom (DXCM)
Market Cap: $33.79 billion
Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ: DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks.
Why Should You Buy DXCM?
- Core business is healthy and doesn’t need acquisitions to boost sales as its organic revenue growth averaged 12% over the past two years
- Free cash flow margin increased by 20.2 percentage points over the last five years, giving the company more capital to invest or return to shareholders
- Returns on capital are climbing as management makes more lucrative bets
DexCom is trading at $87.35 per share, or 31.2x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
